Catalent Completes Accucaps Acquisition
PTSM: Pharmaceutical Technology Sourcing and Management
The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity.
CDMO Catalent announced that it has completed the acquisition of Accucaps, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency and conventional pharmaceutical softgels. No financial details of the transaction were disclosed.
The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity, adding a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing, and packaging. Accucaps’ facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s. More than 500 employees at Accucaps at the facilities in Windsor and Strathroy, Ontario, have joined Catalent’s network of 11 softgel technologies facilities.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
